868755-53-7

Basic information

• Product Name: 6-Morpholin-4-ylpyridine-2-carbonitrile
• Synonyms: 6-MORPHOLIN-4-YLPYRIDINE-2-CARBONITRILE;6-Morpholinopicolinonitrile
• CAS NO: 868755-53-7
• Molecular Formula: C10H11N3O
• Molecular Weight: 189.21384
• Mol File: 868755-53-7.mol
• Article Data: 3

Chemical Properties

• Melting Point: 133 °C
• Boiling Point: 388.3°C at 760 mmHg
• Flash Point: 188.6°C
• Appearance: /
• Density: 1.23g/cm³
• Vapor Pressure: 3.11E-06mmHg at 25°C
• Refractive Index: 1.585
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-Morpholin-4-ylpyridine-2-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Morpholin-4-ylpyridine-2-carbonitrile(868755-53-7)
• EPA Substance Registry System: 6-Morpholin-4-ylpyridine-2-carbonitrile(868755-53-7)

Safety Data

• Hazardous Substances Data: 868755-53-7(Hazardous Substances Data)

Usage

Description

6-Morpholin-4-ylpyridine-2-carbonitrile is a heterocyclic chemical compound with the molecular formula C13H12N4O. It features a morpholine ring and a pyridine ring, along with a carbonitrile functional group. 6-Morpholin-4-ylpyridine-2-carbonitrile plays a significant role in medicinal chemistry, particularly as an intermediate in the synthesis of pharmaceuticals and agrochemicals.

Uses

Used in Pharmaceutical Industry:
6-Morpholin-4-ylpyridine-2-carbonitrile is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows it to be a versatile building block for the development of potential drugs targeting a wide range of therapeutic areas.
Used in Agrochemical Industry:
In the agrochemical sector, 6-Morpholin-4-ylpyridine-2-carbonitrile serves as an intermediate in the production of agrochemicals. Its incorporation into these compounds can contribute to the development of effective solutions for pest control and crop protection.
Used in Medicinal Chemistry Research:
6-Morpholin-4-ylpyridine-2-carbonitrile is utilized as a lead compound in medicinal chemistry research. Its potential biological activities make it a promising candidate for further drug discovery and development, paving the way for new treatments and therapies.

InChI:InChI=1/C10H11N3O/c11-8-9-2-1-3-10(12-9)13-4-6-14-7-5-13/h1-3H,4-7H2

Upstream product

• 143-33-9 sodium cyanide 
• 544-92-3 copper(I) cyanide 
• 332134-60-8 4-(6-bromopyridin-2-yl)morpholine 
• 1061750-16-0 6-(morpholin-4-yl)pyridine-2-carboxamide 
• 407-25-0 trifluoroacetic anhydride 
• 21190-87-4 6-bromo-pyridine-2-carboxylic acid 
• 1061750-15-9 ethyl 6-(morpholin-4-yl)pyridine-2-carboxylate 
• 110-91-8 morpholine 
• 3939-15-9 6-fluoropyridine-2-carbonitrile 

Relevant articles and documents

PYRAZINE COMPOUNDS AND USES THEREOF

The present disclosure novel pyrazine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.

Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6- pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease

4-Acetylamino-2-(3,5-dimethylpyrazol-1-yl)-pyrimidines bearing substituted pyridyl groups as C-6 substituents were prepared as selective adenosine hA 2A receptor antagonists for the treatment of Parkinson's disease. The 5-methoxy-3-pyridyl derivative 6g (hA2A Ki 2.3 nM, hA1 Ki 190 nM) was orally active at 3 mg/kg in a rat HIC model but exposure was poor in nonrodent species, presumably due to poor aqueous solubility. Follow-on compound 16a (hA2A Ki 0.83 nM, hA1 Ki 130 nM), bearing a 6-(morpholin-4-yl)-2-pyridyl substituent at C-6, had improved solubility and was orally efficacious (3 mg/kg, HIC) but showed time-dependent cytochrome P450 3A4 inhibition, possibly related to morpholine ring metabolism. Compound 16j (hA2A Ki 0.44 nM, hA1 Ki 80 nM), bearing a 6-(4-methoxypiperidin-1-yl)- 2-pyridyl substituent at C-6, was sparingly soluble but had good oral exposure in rodent and nonrodent species, had no cytochrome P450 or human ether-a-go-go related gene channel issues, and was orally efficacious at 1 mg/kg in HIC and at 3 mg/kg for potentiation of L-dopa-induced contralateral rotations in 6-hydroxydopamine-lesioned rats.